Figure 3From: Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolismPredicted plasma rivaroxaban concentration–time profiles. ‘Typical’ patients and those with extremes of age, renal function and body weight receiving rivaroxaban 20 mg once daily. Reproduced with permission from Mueck W et al. [16]. CLCR, creatinine clearance.Back to article page